Previous close | 6.7200 |
Open | 2.3000 |
Bid | 3.3000 |
Ask | 6.5000 |
Strike | 100.00 |
Expiry date | 2025-01-17 |
Day's range | 2.3000 - 3.3000 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.20 on 13th of...
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like a
Novartis ( VTX:NOVN ) Full Year 2022 Results Key Financial Results Revenue: US$51.8b (down 2.0% from FY 2021). Net...